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Morphogenic cues that modulate podocyte growth
The apical surfaces of glomerular podocytes and tubular epi-
thelium bathe in the tubular brine of filtering nephrons. In effect
they reside outside the body proper and a certain percentage will
regularly slough into the rivulet. When this happens, neighboring
epithelial cells still attached to basement membrane have several
options. They can go ahead like their predecessors and kill
themselves by apoptosis, they can hypertrophy to fill the empty
space, they can divide to restore what was lost, or they can
partially divide and remain polyploid and dysfunctional. Today,
we know many of these choices are dictated by cell-cycle regula-
tory proteins.
There is varied capacity for cell division among the many types
of renal epithelium [1]. Such phenotypic differences are attribut-
able to variations in highly-ordered chromatin tempered by
environmental signals and the necessities of a highly differenti-
ated state. What biomodulates the propensity of cells to hyper-
trophy or divide rather than apoptose has been pouring out of
cell-cycle laboratories for several years [2]. Ever increasingly, this
work has started to interface with the biology of adhesion and the
morphogenic cues provided by cell substratum [3].
A paper in this issue of Kidney International by Combs and
colleagues is particularly timely [4]. Combs reports that p27Kip1,
one of a growing hand full of recently described cyclin-dependent
kinase (CDK) inhibitors that negatively regulate the G1/S transi-
tion of the cell-cycle, is not expressed during early human
nephrogenesis. As these nephrons mature, however, p27Kip1
constitutively expresses largely in mature podocytes, and not in
mesangial cells or glomerular endothelium. CDK inhibitors like
p27Kip1 work by inserting into the catalytic clefts of early cyclin-
CDK complexes. When this happens the complex looses its kinase
activity, the retinoblastoma protein remains hypophosphorylated,
and cell proliferation is inhibited. The hyperproliferation of cells
and tumors found in p27Kip1 knockout mice suggests its impor-
tance to differentiated organ tissues [5]. Constitutive expression of
p27Kip1 in mature nephrons therefore neatly explains why podo-
cytes have the lowest proliferative rate in the kidney [1] and why
these cells have limited regenerative capacity following injury [6].
Recently, a shorter carboxyterminal form of p27Kip1 has been
found in fibroblasts which reach maximum during the G2/M phase
and actually enhances the CDKs active in the transition to mitosis
[7]. One notion, albeit unproven, is that p27Kip1 lacking its full
amino-terminus is a “shaving from the carpenter’s bench” that
leaks from ubiquitin-proteosome degradation complexes after
release of the G1/S clamp. Thus, after opening G1/S transition,
these remnants may facilitate cell-cycle progression by activating
downstream kinases.
Cell hypertrophy is a phenotypic alternative for differentiated
epithelium. Hypertrophy of tubular cells, unlike passive osmotic
swelling, requires that the cell go through a G0/G1 transition
[8–10]. The next step in this process is the placement of a clamp
on G1/S transition, preventing completion of the cell-cycle [11].
Recent evidence indicates p27Kip1 can be that clamp in hypertro-
phy. For example, angiotensin II-mediated tubular hypertrophy
[12], a mechanism most likely contributing to compensatory renal
growth following the loss of functioning renal tissue, as well as the
hypertrophy forced on mesangial cells by the diabetic milieu [13],
are dependent on p27Kip1 accumulation.
One question not answered by Combs’ work is why p27Kip1 is
only constitutively expressed in mature podocytes. For conjecture
and partial satisfaction we can look to several new leads from the
world of collagen and basement membrane biochemistry. Vascu-
lar smooth muscle cells grown in culture on interstitial type I
collagen induces p27Kip1 to inhibit cell growth [14]. This effect
depends on a2 integrin-mediated attachments and is a critical
regulator of CDK inhibitors. Epithelium of course are probably
more differentiated than smooth muscle cells, and they organize
into specialized units to coordinate function. These epithelial
units rest on a complex basement membrane comprising several
species of type IV collagen, laminins, various proteoglycans,
entactin, and nidogen. Attachment to this membrane initiates cell
polarity and specifies protein content [3].
Since not all basement membranes are biochemically homoge-
nous, their diversity can be a morphogenic cue that differentially
modulates the biologic properties of attached epithelium. In the
case of the glomerular basement membrane (GBM), for example,
the type IV collagen species in forming capillary loops undergoes
a developmental switch during human nephrogenesis [15]. GBM
collagen in early nephrogenesis is comprised of only a1 and
a2(IV) isoforms. As the tuft begins to mature, however, it
becomes predominantly enriched with chains of a3, a4, and
a5(IV) collagens. These new, specialized isoforms are highly
cross-linked [16] and more resistant to proteases [15]. Further
evidence suggests that residual a1 and a2(IV) collagens in GBM
are partitioned more towards the subendothelium, while the
newer a3, a4, and a5(IV) isoforms tend more to the subepithelial
lamination [17]. This may be necessary for the establishment of
permselectivity.
Why this arrangement of type IV collagen in GBM is important
to the control of podocyte proliferation is suggested by cell
adherence studies that describe an a3b1 integrin binding prefer-
ence for the non-collagenous (NC1) domain of a3(IV) collagen
over a1(IV) NC1 domains [18]. Additionally, a unique peptide
region found in the a3(IV) NC1 domain (residues 185-203) but
not in the other chains of type IV collagen has an antiproliferative
effect on attached cells [19]. If these specialized regions of the
a3(IV) NC1 domain have important antiproliferative effects on
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podocytes, one might reasonably speculate this pathway could
transduce the p27Kip1 signal in mature but not developing glomer-
ular epithelium.
Why then isn’t p27Kip1 also constitutively expressed in glomer-
ular endothelium? One possibility is that endothelium interacts
with a preferred region found in the a1(IV) NC1 domain of type
IV collagen [20]. Additionally, other unexplored matrix molecules
in the GBM, particularly laminin, may contribute a modulating
influence that is not yet appreciated. Under pathological condi-
tions, interaction specificity may be further disturbed by inflam-
matory cell proteases that disintegrate GBM altering the expres-
sion patterns of CDK inhibitors in surrounding cells.
Finally, when the glomerular tuft is experimentally injured one
might expect podocytes to proliferate. Surprisingly, this does not
usually happen because the levels of p27Kip1 in podocytes increase
[10] and the number of cells typically remain the same [6]. More
often than not polyploidy and failure of cytokinesis are seen, and
these changes may hamper nephron filtration by leaving the
basement membrane denuded from injury or epithelial instability.
Such disturbances likely contribute to the persistence of protein-
uria that facilitates the downstream cytokine bath associated with
nephrosclerosis [21] and progressive fibrogenesis of the tubular
interstitium [22]. Equally, in the absence of external injury, the
nephrosclerosis one sees from aging may be rooted in the
podocyte’s inability to overcome p27Kip1’s anti-proliferative clamp
on G1/S. p27Kip1 may turn out to be a significant obstacle to
eternal life for human kidneys.
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